Key Highlights From the PERSEUS and CASSIOPEIA Studies

Opinion
Video

Panelists discuss how recent pivotal trials like PERSEUS and CASSIOPEIA demonstrate superior outcomes with daratumumab-based quadruplet and triplet combinations compared with standard regimens in transplant-eligible newly diagnosed multiple myeloma patients, particularly showing improved progression-free survival when daratumumab is added to VRd (bortezomib, lenalidomide, and dexamethasone) or VTd (bortezomib, thalidomide, and dexamethasone) backbones.

CN24_ATP_NDMM_Seg02_PERSEUS
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Let’s begin our discussion with newly diagnosed multiple myeloma, specifically in patients who are transplant eligible. Can you briefly comment on recent updates surrounding combination therapies for transplant-eligible NDMM:
      • Dara-VRd vs VRd
      • Dara-VTd vs VTd

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Related Content